abstract |
This disclosure relates in part to heterocycles and their use in the treatment of medical disorders such as immunoinflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatism, psoriasis and allergy. The compounds are expected to modulate T-cell responses. |